A multicenter controlled, randomized, open trial of interferon α2b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis C

Maria Grazia Rumi, Elena Santagostino, M. Morfini, A. Gringeri, G. Tagariello, A. Chistolini, Patrizia Pontisso, A. Tagger, M. Colombo, P. M. Mannucci

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

There is limited information about the long-term efficacy of prolonged therapy (more than 6 months) with interferon in hemophilic patients with chronic hepatitis C who are not coinfected with the human immunodeficiency virus (HIV-1). One hundred and seven hemophiliacs were randomly assigned to 3 million U of interferon α2b three times weekly for 12 months or no therapy. The patients were followed up for at least 12 months posttreatment. Response was assessed by both serial alanine aminotransferase (ALT) levels and hepatitis C virus (HCV)-RNA measured by reverse transcribed polymerase chain reaction (RT-PCR) method. Before treatment, serum levels of HCV-RNA were measured quantitatively by second-generation branched-DNA assay and the HCV genotype was determined by RT-PCR. Serum HGV-RNA, a marker of infection with the hepatitis G virus, was also measured by RT-PCR. Normalization of ALT was sustained end serum HCV-RNA was cleared in 6 of 45 treated patients, compared with none of the 50 untreated controls (13% v 0% P <.01). Low pretreatment viremia was the only feature that was associated with an increased likelihood of sustained response (P <.01). This study shows that multitransfused hemophiliacs with chronic hepatitis C not coinfected with HIV-1 respond at low rates to prolonged interferon therapy.

Original languageEnglish
Pages (from-to)3529-3533
Number of pages5
JournalBlood
Volume89
Issue number10
Publication statusPublished - May 15 1997

Fingerprint

Chronic Hepatitis C
Viruses
Hepacivirus
Interferons
Randomized Controlled Trials
HIV
RNA
HIV-1
Polymerase chain reaction
Alanine Transaminase
Polymerase Chain Reaction
Branched DNA Signal Amplification Assay
Serum
GB virus C
Viremia
Therapeutics
Genotype
Assays
Infection
DNA

ASJC Scopus subject areas

  • Hematology

Cite this

A multicenter controlled, randomized, open trial of interferon α2b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis C. / Rumi, Maria Grazia; Santagostino, Elena; Morfini, M.; Gringeri, A.; Tagariello, G.; Chistolini, A.; Pontisso, Patrizia; Tagger, A.; Colombo, M.; Mannucci, P. M.

In: Blood, Vol. 89, No. 10, 15.05.1997, p. 3529-3533.

Research output: Contribution to journalArticle

Rumi, Maria Grazia ; Santagostino, Elena ; Morfini, M. ; Gringeri, A. ; Tagariello, G. ; Chistolini, A. ; Pontisso, Patrizia ; Tagger, A. ; Colombo, M. ; Mannucci, P. M. / A multicenter controlled, randomized, open trial of interferon α2b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis C. In: Blood. 1997 ; Vol. 89, No. 10. pp. 3529-3533.
@article{4354281230b14826b4f9bc76d9a3d069,
title = "A multicenter controlled, randomized, open trial of interferon α2b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis C",
abstract = "There is limited information about the long-term efficacy of prolonged therapy (more than 6 months) with interferon in hemophilic patients with chronic hepatitis C who are not coinfected with the human immunodeficiency virus (HIV-1). One hundred and seven hemophiliacs were randomly assigned to 3 million U of interferon α2b three times weekly for 12 months or no therapy. The patients were followed up for at least 12 months posttreatment. Response was assessed by both serial alanine aminotransferase (ALT) levels and hepatitis C virus (HCV)-RNA measured by reverse transcribed polymerase chain reaction (RT-PCR) method. Before treatment, serum levels of HCV-RNA were measured quantitatively by second-generation branched-DNA assay and the HCV genotype was determined by RT-PCR. Serum HGV-RNA, a marker of infection with the hepatitis G virus, was also measured by RT-PCR. Normalization of ALT was sustained end serum HCV-RNA was cleared in 6 of 45 treated patients, compared with none of the 50 untreated controls (13{\%} v 0{\%} P <.01). Low pretreatment viremia was the only feature that was associated with an increased likelihood of sustained response (P <.01). This study shows that multitransfused hemophiliacs with chronic hepatitis C not coinfected with HIV-1 respond at low rates to prolonged interferon therapy.",
author = "Rumi, {Maria Grazia} and Elena Santagostino and M. Morfini and A. Gringeri and G. Tagariello and A. Chistolini and Patrizia Pontisso and A. Tagger and M. Colombo and Mannucci, {P. M.}",
year = "1997",
month = "5",
day = "15",
language = "English",
volume = "89",
pages = "3529--3533",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "10",

}

TY - JOUR

T1 - A multicenter controlled, randomized, open trial of interferon α2b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis C

AU - Rumi, Maria Grazia

AU - Santagostino, Elena

AU - Morfini, M.

AU - Gringeri, A.

AU - Tagariello, G.

AU - Chistolini, A.

AU - Pontisso, Patrizia

AU - Tagger, A.

AU - Colombo, M.

AU - Mannucci, P. M.

PY - 1997/5/15

Y1 - 1997/5/15

N2 - There is limited information about the long-term efficacy of prolonged therapy (more than 6 months) with interferon in hemophilic patients with chronic hepatitis C who are not coinfected with the human immunodeficiency virus (HIV-1). One hundred and seven hemophiliacs were randomly assigned to 3 million U of interferon α2b three times weekly for 12 months or no therapy. The patients were followed up for at least 12 months posttreatment. Response was assessed by both serial alanine aminotransferase (ALT) levels and hepatitis C virus (HCV)-RNA measured by reverse transcribed polymerase chain reaction (RT-PCR) method. Before treatment, serum levels of HCV-RNA were measured quantitatively by second-generation branched-DNA assay and the HCV genotype was determined by RT-PCR. Serum HGV-RNA, a marker of infection with the hepatitis G virus, was also measured by RT-PCR. Normalization of ALT was sustained end serum HCV-RNA was cleared in 6 of 45 treated patients, compared with none of the 50 untreated controls (13% v 0% P <.01). Low pretreatment viremia was the only feature that was associated with an increased likelihood of sustained response (P <.01). This study shows that multitransfused hemophiliacs with chronic hepatitis C not coinfected with HIV-1 respond at low rates to prolonged interferon therapy.

AB - There is limited information about the long-term efficacy of prolonged therapy (more than 6 months) with interferon in hemophilic patients with chronic hepatitis C who are not coinfected with the human immunodeficiency virus (HIV-1). One hundred and seven hemophiliacs were randomly assigned to 3 million U of interferon α2b three times weekly for 12 months or no therapy. The patients were followed up for at least 12 months posttreatment. Response was assessed by both serial alanine aminotransferase (ALT) levels and hepatitis C virus (HCV)-RNA measured by reverse transcribed polymerase chain reaction (RT-PCR) method. Before treatment, serum levels of HCV-RNA were measured quantitatively by second-generation branched-DNA assay and the HCV genotype was determined by RT-PCR. Serum HGV-RNA, a marker of infection with the hepatitis G virus, was also measured by RT-PCR. Normalization of ALT was sustained end serum HCV-RNA was cleared in 6 of 45 treated patients, compared with none of the 50 untreated controls (13% v 0% P <.01). Low pretreatment viremia was the only feature that was associated with an increased likelihood of sustained response (P <.01). This study shows that multitransfused hemophiliacs with chronic hepatitis C not coinfected with HIV-1 respond at low rates to prolonged interferon therapy.

UR - http://www.scopus.com/inward/record.url?scp=8244260075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8244260075&partnerID=8YFLogxK

M3 - Article

VL - 89

SP - 3529

EP - 3533

JO - Blood

JF - Blood

SN - 0006-4971

IS - 10

ER -